Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background —The optimal duration of oral anticoagulant therapy after a first episode of venous thromboembolism remains controversial. Methods and Results —We performed an open-label, randomized trial comparing a short oral anticoagulant course (3 months for proximal deep vein thrombosis [P-DVT] and/or pulmonary embolism [PE]; 6 weeks for isolated calf DVT [C-DVT]) with a long course of therapy (6 months for P-DVT/PE; 12 weeks for C-DVT). The outcome events were recurrences and major, minor, or fatal bleeding complications. A total of 736 patients were enrolled. There were 23 recurrences of venous thromboembolism in the short treatment group (6.4%) and 26 in the long treatment group (7.4%); the 2 treatment regimens had an equivalent effect. For the hemorrhage end point, the difference between the short and the long treatment groups was not significant: 15.5% versus 18.4% for all events ( P =0.302), 1.7% versus 2.8% ( P =0.291) for major events, and 13.9% versus 15.3% for minor bleeding. Subgroup analysis demonstrated that the rate of recurrence was lower for C-DVT than for P-DVT or PE. Conclusions —After isolated C-DVT, 6 weeks of oral anticoagulation is sufficient. For P-DVT or PE, we demonstrated an equivalence between 3 and 6 months of anticoagulant therapy. For patients with temporary risk factors who have a low risk of recurrence, 3 months of treatment seems to be sufficient. For patients with idiopathic venous thromboembolism or permanent risk factors who have a high risk of recurrence, other trials are necessary to assess prolonged therapy beyond 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
Landefeld, C. S., & Beyth, R. J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90285-w · Cited by 893
Beyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
Prandoni, P., Lensing, A. W. A., Büller, H. R., Cogo, A., Prins, M. H., Cattelan, A. M., Cuppini, S., Noventa, F., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210153271604 · Cited by 680
Hirsh, J., & Hoak, J. (1996) · Circulation · doi:10.1161/01.cir.93.12.2212 · Cited by 635
O'Neill, D. D., Westerman, D. P., & Sacco, W. (1966) · doi:10.21236/ad0635168 · Cited by 566
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Incidence and mortality of venous thrombosis: a population‐based study
NÆSS, I. A., CHRISTIANSEN, S. C., ROMUNDSTAD, P., CANNEGIETER, S. C., ROSENDAAL, F. R., & HAMMERSTRØM, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02450.x · Cited by 1,413
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
The epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,093
Natural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Prandoni, P., Noventa, F., Ghirarduzzi, A., Pengo, V., Bernardi, E., Pesavento, R., Iotti, M., Tormene, D., Simioni, P., & Pagnan, A. (2007) · Haematologica · doi:10.3324/haematol.10516 · Cited by 776
Linkins, L.-A., Choi, P. T., & Douketis, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00007 · Cited by 764
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
British Thoracic Society guidelines for the management of suspected acute pulmonary embolism
(2003) · Thorax · doi:10.1136/thorax.58.6.470 · Cited by 686
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054444 · Cited by 622
Kyrle, P. A., & Eichinger, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71880-8 · Cited by 616
Guidelines on oral anticoagulation with warfarin – fourth edition
Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S., Makris, M., & British Committee for Standards in Haematology (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08753.x · Cited by 586
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
“Oral anticoagulation therapy is very effective for reducing the risk of recurrence during therapy (> 90% relative risk [RR] reduction);(3,4,10,11) however, this benefit is lost after therapy is discontinued.(3,10,11) The risk of major bleeding with ongoing oral anticoagulation therapy among venous thromboembolism pati…”
BackgroundResidual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
Prandoni, P., Lensing, A. W. A., Prins, M. H., Bernardi, E., Marchiori, A., Bagatella, P., Frulla, M., Mosena, L., Tormene, D., Piccioli, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00008 · Cited by 547
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., & Schulman, S. (2004) · Chest · doi:10.1378/chest.126.3_suppl.287s · Cited by 515
British Thoracic Society guidelines for the management of suspected acute pulmonary embolism
Campbell, I. A., Fennerty, A., & Miller, A. C. (2005) · PULMONOLOGIYA · doi:10.18093/0869-0189-2005-0-4-19-39 · Cited by 458
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
Schulman, S., Wåhlander, K., Lundström, T., Clason, S. B., & Eriksson, H. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030104 · Cited by 454
Venous thromboembolism: disease burden, outcomes and risk factors
HEIT, J. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01415.x · Cited by 447
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Acute Pulmonary Embolism: Part I: Epidemiology, Pathophysiology, and Diagnosis
Goldhaber, S. Z., & Elliott, C. G. (2003) · Circulation · doi:10.1161/01.cir.0000097829.89204.0c · Cited by 406
Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism
Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M. R., Miccio, M., Imberti, D., Poggio, R., Ageno, W., Pogliani, E., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-1-200307010-00008 · Cited by 400
Guidelines on oral anticoagulation (warfarin): third edition – 2005 update
Baglin, T. P., Keeling, D. M., Watson, H. G., & the British Committee for Standards in Haematology (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05856.x · Cited by 392
Heit, J. A. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5572-y · Cited by 383
Boutitie, F., Pinede, L., Schulman, S., Agnelli, G., Raskob, G., Julian, J., Hirsh, J., & Kearon, C. (2011) · BMJ · doi:10.1136/bmj.d3036 · Cited by 371
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
Khan, F., Rahman, A., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Eichinger, S., Kyrle, P. A., Becattini, C., et al. (2019) · BMJ · doi:10.1136/bmj.l4363 · Cited by 328
Self-citationD-Dimer Levels and Risk of Recurrent Venous Thromboembolism
Eichinger, S. (2003) · JAMA · doi:10.1001/jama.290.8.1071 · Cited by 327
Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Kearon, C., & Akl, E. A. (2014) · Blood · doi:10.1182/blood-2013-12-512681 · Cited by 279
Palareti, G., Legnani, C., Cosmi, B., Valdré, L., Lunghi, B., Bernardi, F., & Coccheri, S. (2003) · Circulation · doi:10.1161/01.cir.0000079162.69615.0f · Cited by 276
López, J. A., Kearon, C., & Lee, A. Y. Y. (2004) · Hematology · doi:10.1182/asheducation-2004.1.439 · Cited by 272
Treatment of Deep-Vein Thrombosis
Bates, S. M., & Ginsberg, J. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031676 · Cited by 265
Rodger, M. A., Le Gal, G., Anderson, D. R., Schmidt, J., Pernod, G., Kahn, S. R., Righini, M., Mismetti, P., Kearon, C., Meyer, G., et al. (2017) · BMJ · doi:10.1136/bmj.j1065 · Cited by 238
Prandoni, P., Prins, M. H., Lensing, A. W. A., Ghirarduzzi, A., Ageno, W., Imberti, D., Scannapieco, G., Ambrosio, G. B., Pesavento, R., Cuppini, S., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00003 · Cited by 232
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Middeldorp, S., Prins, M. H., & Hutten, B. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001367.pub3 · Cited by 133
Alfonso, A., Jiménez, D., Capitán, C. F., Prandoni, P., Wells, P. S., Vidal, G., Barillari, G., Monreal, M., Lecumberri, R., & and the RIETE Investigators (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0132 · Cited by 129
(2008) · PubMed Central · Cited by 46
Oral anticoagulation strategies after a first idiopathic venous thromboembolic event
Aujesky, D., Smith, K. J., & Roberts, M. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.018 · Cited by 29
Streiff, M. B., Segal, J. B., Tamariz, L. J., Jenckes, M. W., Bolger, D. T., Eng, J., Krishnan, J. A., & Bass, E. B. (2006) · American Journal of Hematology · doi:10.1002/ajh.20691 · Cited by 17
Holley, A. B., King, C. S., Jackson, J. L., & Moores, L. K. (2010) · Thrombosis · doi:10.1155/2010/540386 · Cited by 10
Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis
Ost, D., Tepper, J., Mihara, H., Lander, O., Heinzer, R., & Fein, A. (2005) · JAMA · doi:10.1001/jama.294.6.706 · Cited by 3
Metadata
- Authors
- Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C., & Boissel, J.-P.
- Venue
- Circulation
- Published
- 2001-05-22
- Volume
- 103
- Issue
- 20
- Pages
- 2453-2460
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2073192852
- Cited by
- 408
- References
- 25
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.